CD274 and neoplasm: The response of patients treated with ICIs may be influenced by immune-related genes (IRGs), such as programmed death-1 (PD-1) and PD-L1 in the tumor microenvironment (TME) [14,15], tumor-infiltrating immune cells (TICs) [16,17], tumor mutation burden (TMB) [18], and the expression of immune-related signaling pathways [19] in the TME, which may have an impact on the clinical outcome of patients treated with ICIs [20].